Ignite Creation Date:
2025-12-25 @ 3:55 AM
Ignite Modification Date:
2026-02-27 @ 3:13 AM
Study NCT ID:
NCT02906202
Status:
COMPLETED
Last Update Posted:
2023-06-18
First Post:
2016-08-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
Sponsor:
Genetix Biotherapeutics Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-08
Start Date Type:
ACTUAL
Primary Completion Date:
2022-03-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-03-31
Completion Date Type:
ACTUAL
First Submit Date:
2016-08-19
First Submit QC Date:
None
Study First Post Date:
2016-09-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-03-23
Results First Submit QC Date:
None
Results First Post Date:
2023-06-18
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-22
Last Update Post Date:
2023-06-18
Last Update Post Date Type:
ACTUAL